Episode 3: The Biopharma Exit Strategy With Dr. Francois Nader
Source: Cytiva

Every new, emerging biopharma company shares a common goal: creating value for its employees, its board, its investors, and ultimately, patients. Along the way, that value creating might get a boost from an IPO, a merger, an acquisition, or steady growth as a private entity. On this episode of The Business Of Biotech, we talk with Dr. Francois Nader—a man who's orchestrated several wildly successful biotech exits—about why it's imperative to begin with the end in mind, and how to navigate your options when the time is right.
LISTEN TO THE PODCAST!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Cell & Gene? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more